Molecule News and Research

RSS

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Researchers at the University of California Los Angeles (UCLA) have found that a second molecular pathway may need to be blocked to prevent malignant cells from creating new blood vessels [angiogenesis]. A study of patients with pancreatic cancer showed that CXCL5 may be a key molecule in the angiogenesis switch—the point at which cells stop being normal and start producing blood vessels that feed malignancy.

14 Oct 2009

Brain researcher finds how the epilepsy and pain drug works

A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works.

14 Oct 2009

Increase in adiponectin hormone levels protects against sepsis-related mortality

A hormone naturally found in the fat that surrounds the abdominal organs for the first time has been linked to death related to sepsis, surgeons reported at the 2009 Clinical Congress of the American College of Surgeons. A study exhibited at the conference showed that low levels of the hormone adiponectin placed animals at a profoundly high risk of death from a septic insult.

14 Oct 2009

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Galapagos NV announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.

14 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields.

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Arch Pharmalabs collaborates with Orochem Technologies to manufacture an API in India

Arch Pharmalabs, Ltd., a leading provider of small molecule process R&D and full life-cycle custom synthesis and manufacturing services, announced today it has entered into a strategic partnership with Orochem Technologies, Inc., to manufacture a U.S. innovator’s active pharmaceutical ingredient (API) in late-stage clinical development using Simulated Moving Bed (SMB) technology.

12 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Transgenomic, Inc. (OTC Bulletin Board: TBIO). The company announced today that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI), Boston, MA.

9 Oct 2009

Helicos Biosciences awarded a $2.9M NIH grant

Helicos BioSciences Corporation announced today that it is the recipient of an award from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH).

8 Oct 2009

Pacific Biosciences is the Overall Winner of the OnDC 100 Top Private Company Awards

AlwaysOn today announced the winners of its OnDC 100 Top Private Company Awards and named Pacific Biosciences the Overall Winner. Inclusion in the OnDC 100 signifies technology developments in healthcare, education, broadband infrastructure, green technology, enterprise and cybersecurity that contribute to the renewed and continued prosperity of our country.

8 Oct 2009

NIH awards $1.9 million grant to Pacific Biosciences

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today announced that it has received grants totaling more than $1.9 million from the National Institutes of Health (NIH) as part of the American Recovery & Reinvestment Act of 2009 Research and Research Infrastructure “Grand Opportunities” grants program.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

New mechanism of bone formation may help fight osteoporosis

The natural cycle of building bone to maintain skeletal strength and then breaking it down for the body's calcium needs is delicately balanced, but diseases like osteoporosis break down too much bone without adequate bone replacement, leading to bone fractures.

8 Oct 2009

Molecule News and Research

Resveratrol in red grapes offers some protection against diabetes

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Brain researcher finds how the epilepsy and pain drug works

Increase in adiponectin hormone levels protects against sepsis-related mortality

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Arch Pharmalabs collaborates with Orochem Technologies to manufacture an API in India

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Manchester scientists test radioimmunotherapy in early phase clinical trials

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Helicos Biosciences awarded a $2.9M NIH grant

Pacific Biosciences is the Overall Winner of the OnDC 100 Top Private Company Awards

NIH awards $1.9 million grant to Pacific Biosciences

Mimetogen Pharmaceuticals completes its equity financing

New mechanism of bone formation may help fight osteoporosis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News